Backed by gi­ants, an­tibi­otics up­start Macrolide gets $20M and an ex-No­var­tis ex­ec as CEO

An an­tibi­otics start­up found­ed by the same guy who start­ed boom-and-bust an­tibi­otics com­pa­ny Tetraphase has hauled in $20 mil­lion in new cap­i­tal and a long­time No­var­tis ex­ec­u­tive as its new pres­i­dent and CEO.

With cash in hand and a new chief at the helm, the com­pa­ny plans to tack­le some of the most dan­ger­ous su­per­bugs around by tweak­ing an old class of an­tibi­otics.

Wa­ter­town, MA-based Macrolide Phar­ma­ceu­ti­cals raised the Se­ries B round from three phar­ma gi­ants, in­clud­ing the ven­ture arms of Glax­o­SmithK­line (SR One), No­var­tis (No­var­tis Ven­ture Fund), and Roche (Roche Ven­tures), among oth­er in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER